8-K: Oscar Health Launches $350M Convertible Notes Offering

Oscar Health, Inc. announced a proposed private offering of $350 million in convertible senior subordinated notes due 2030 to fund growth initiatives and general corporate purposes.

Summary

• Oscar Health, Inc. intends to offer $350,000,000 aggregate principal amount of convertible senior subordinated notes due 2030 in a private offering to qualified institutional buyers.
• The company expects to grant initial purchasers an option to buy an additional $52,500,000 aggregate principal amount of notes.
• Net proceeds will be used for general corporate purposes, including future expansion fueled by strategic AI initiatives, lowering the cost of care, enhancing consumer healthcare experiences, and supporting the potential extension of enhanced premium tax credits.
• A portion of the net proceeds will fund capped call transactions designed to reduce potential stock dilution upon conversion of the notes.
• The notes will be unsecured, subordinated indebtedness, accruing interest semi-annually and maturing on September 1, 2030.
• Oscar expects to give notice of its intent to terminate its revolving credit facility, contingent on the closing of the offering and expected to occur concurrently.
• An amendment to the Investment Agreement with Dragoneer Investment Group, LLC, dated January 27, 2022, was entered into on September 11, 2025, to permit this offering.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company is proactively securing significant capital for strategic growth initiatives, including AI and member experience enhancements, and is taking steps to manage potential dilution through capped call transactions. The planned termination of the revolving credit facility also suggests a more streamlined debt structure. However, the introduction of new subordinated debt and the inherent risks associated with convertible notes and market conditions temper the overall positive outlook.

Positives

• Securing $350 million (potentially up to $402.5 million) in capital for strategic growth initiatives and general corporate purposes.
• Funds will support future expansion, including AI initiatives, efforts to lower the cost of care, and enhancing consumer healthcare experiences.
• The offering provides capital for additional growth opportunities, such as the potential extension of enhanced premium tax credits.
• Capped call transactions are expected to reduce potential dilution to Class A common stock upon conversion of the notes and/or offset potential cash payments in excess of the principal amount.
• The company expects to terminate its revolving credit facility, which could simplify its debt structure and reduce associated costs.

Negatives

• The notes are unsecured and subordinated to Oscar's designated senior indebtedness, placing them lower in priority for repayment.
• Potential dilution to Class A common stock could still occur if the market price per share exceeds the cap price of the capped call transactions.
• Hedging activities by option counterparties could cause or avoid increases or decreases in the market price of Oscar's Class A common stock or the notes, potentially affecting noteholders' ability to convert or the value received.

Risks

• Market conditions, including market interest rates, could impact the offering.
• The trading price and volatility of Oscar's Class A common stock could affect the value of the notes and potential dilution.
• General business risks, as detailed in the company's SEC filings (Form 10-K for 2024, Form 10-Q for Q1 and Q2 2025), apply.
• The option counterparties' hedging activities could influence the market price of Oscar's stock or notes, affecting conversion outcomes.

Future Outlook

Oscar Health plans to use the proceeds from the offering to support future expansion driven by strategic initiatives focused on artificial intelligence, lowering the cost of care, and enhancing consumer healthcare experiences. The funds will also support additional growth opportunities, including the potential extension of enhanced premium tax credits.

Management Comments

• Oscar Health intends to use net proceeds from the Offering for general corporate purposes, including to support future expansion fueled by strategic initiatives focused on AI, lowering the cost of care, and enhancing consumer healthcare experiences.
• The funds will also support additional growth opportunities, including the potential extension of enhanced premium tax credits.
• A portion of the net proceeds will be used to fund the cost of entering into capped call transactions to reduce potential dilution.

Industry Context

Oscar Health operates as a leading healthcare technology company, leveraging a full-stack technology platform to serve its members. This capital raise positions the company to further invest in key industry trends such as AI integration in healthcare, cost reduction strategies, and improving consumer engagement and experience, particularly within the individual health insurance market.

Corporate Governance

Related Party Transactions

• An amendment to the Investment Agreement dated January 27, 2022, was entered into with funds affiliated with or advised by Dragoneer Investment Group, LLC, to permit the proposed offering.

Stakeholder Impact

• Shareholders: Potential for future dilution from note conversion, though mitigated by capped call transactions. The capital raise supports growth initiatives that could enhance long-term shareholder value.
• Creditors: New subordinated debt is being introduced, which will rank below senior indebtedness. The revolving credit facility is expected to be terminated.
• Customers/Members: Proceeds are earmarked for initiatives to lower the cost of care and enhance consumer healthcare experiences, potentially leading to improved services.
• Employees: Investment in strategic initiatives like AI and expansion could lead to new opportunities or changes in operational focus.

Next Steps

• Closing of the proposed private offering of convertible senior subordinated notes.
• Entering into privately negotiated capped call transactions with option counterparties.
• Giving notice of intent to terminate the revolving credit facility, contingent on the closing of the offering.

Key Dates

Recommendation

The proposed convertible notes offering provides Oscar Health with significant capital to fund strategic growth initiatives, including advancements in AI and member experience, which are positive for long-term prospects. The use of capped call transactions to mitigate dilution is a prudent financial move. However, the introduction of new debt, even if subordinated, and the inherent market volatility associated with convertible securities and hedging activities, warrant a cautious approach. Investors should hold, monitoring the execution of these growth strategies and the impact of the new financing structure on the company's financial health and stock performance.

Keywords

Oscar Health, OSCR, Convertible Notes, Private Offering, Capital Raise, Healthcare Technology, AI, Growth Initiatives, Debt Financing, SEC Filing